ProAxsis' History in Protease Biomarker Innovation

Founded in 2013 as a spin-out from Queen’s University Belfast, ProAxsis is a commercial-stage biomarker-led research company specialising in active protease biomarker analysis. The company supports pharmaceutical, biotechnology and research organisations through specialist biomarker insight, research-use assays and scientific collaboration.

At the core of ProAxsis’ scientific offering is its proprietary ProteaseTag® technology, designed to selectively capture and measure active protease biomarkers within complex biological samples.

ProAxsis’ patented approach has enabled the generation of high-quality biomarker data to support drug development, translational research and clinical investigation.

More specifically, ProAxsis has developed assays targeting active neutrophil elastase (NE), proteinase 3 (Pr3) and cathepsin G (Cat G), which are protease biomarkers of lung infections and inflammation in chronic respiratory diseases.

The company’s expertise has supported clinical research and biomarker programmes across areas including bronchiectasis, alpha-1 antitrypsin deficiency, COPD and cystic fibrosis.

Building on its deep expertise in the measurement of active proteases, ProAxsis is now working to expand its scientific capabilities across additional biomarkers, applications and disease areas.